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f!om GP!!b/llla to GPIIb/IIIa. from ,~/b to ,,,/~ and from -~P3 to GPltb/llla. 
¢ellecting th~ c0mpa~ affinity of ~x imab for both integrins. 
Conc/us/on: Abciximab can redisthbute between GPllb/llla and . ,~  re- 
ceplora/n vitro, suggesting that abctximab may have proPmged effects on 
~/~ on vascular cells in addition to sustained inhibition of PLT GPIIb/llla. 
• ~t ing  With Abcixlmab (ReoPro'") OeciCases 
Target Lesion Revascularllaflon 
S.K, Shatma, A. Kini, G, Oangas, R. VkJhun, Y. Rajawat, S. Ouvvun, 
J D. Marmur, J.A. Ambrose. Mount Sinai Hospital, New York. USA 
Abciximab (Reopre") has been shown to decrease acute ischemic com- 
plcatK~ns and reduce clinical restenoais following balloon angioplasty and 
coronaw atherectomy. Whether ResPro offers similar benefit after stentmg 
has not been evaluated. We analyzed the 30-day incidence of malor adverse 
cardiac events (MACE) and the need for target lesion revasculanzation (TLR) 
in 388 consecutive stent patients: 78 with ReoPro and 310 wdbout ReoPre. 
Patients with hail-out slanting were excluded. 
Results: As expected, ReoFro was used more frequently in MI and rest 
angina cases ('acute syndromes') and in the setting of multiple stents and 
muttwesset intervention. The incidence of 30-day ~CE did not differ with 
ReoPro. However, the 9-month TLR was sigmticantly lower in the group 
treated with stent plus Reopro compared to stent alone: 
Stent + ReoPro n = 78 Slant alone n = 310 p 
Acute syndromes 68*o 43% 001 
Mu tllless~l $lentlr~j 20% 10% 0 03 
Multiple stents :29°0 21% 0 01 
Procedural Success 98 7°0 98 3% NS 
30-day MACE 1 2=° 22% NS 
Vasculal complications 38% I 6% NS 
TLR 19% 30% 0.02 
MACE = acute/subacute stont hrombosis. Q- ML CABG or death 
Conclusion: The use of RecPro during stenting decreases long-term TLR 
compared to stenting alone. These results were evident even though the 
ReoPro treated group was at higher risk. ReoPre did not affect significantly 
the already low short-term MACE after stenting. Based on these preliminary 
results, the effect of ReoPro on angiographic in-stent restenosis warrants 
prospentLve investigation. 
I 1088-1001 Act ivat ion  of  Platelets in P latelet-r ich Plasma by  
Rotab lat ion  Is Speed Dependent  and Can Be 
Inhib i ted by Abc ix imab (c7E3 Fab; ReoPro") 
MS. Williams, B.S. Coller, H.J. V~n~nen. L.E. Scudder, J.D. Marmur. 
Mount Sinai Hospital New ~brk, New York, USA 
Background: Rotational atherectomy may be complicated by the =no*reflow" 
phenomenon. Because platelet activation may contribute to this complication. 
we developed an in vitro system to test the effect of rotablation on platelets 
in the absence or presence of GPIIb/llla blockade with abciximab. 
Methods: Platelet-nch plasma (PRP) was prepared from 22 healthy hu- 
man volunteers. PRP was divided into four samples: no treatment, 6D1 
(anti-GPIb), abciximab (anti- GPIIb/llla + ~vB3), and abeiximab + 6D1. Sam- 
ples were pumped through a flow chamber containing a 2.5 mm burr rotating 
at various speeds, and then placed in an aggregometer and stirred at 3~C. 
Results: PRP samples tested in the absence of antibody underwent more 
rapid and extensive aggregation when rotablated at 150 and 180k rpm as 
compared to 0 rpm (p .- 0.00001 at both speeds). Preincubation of platelets 
with c7E3 Fab decreasnd the slope of aggregation at each retaliation speed 
(p = 0,09 for 70k and p .- 0,0001 for both 150 and 1801(rpm). The msuffs 
are plotted as mean slope of aggregation • SD vs, rot~blatlon spe l l  Both 
light and electron microscopy revealed rotablat~n~nduced platelet damage 
at 150 and tS0k rpm 
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Conclt~q:  Rolablalion causes speed-depeedenl plaleiel actlvahon in 
PRP which can be ~igniflcantly reduced by pre.lreating PRP with abcil, 
~mab These data s~tggest thai prelreatment of patients w~th abciximab may 
decrease rotablation-induced platelet aggregation dunng mtat~l  atherec- 
ferny, 
I 1088-10111 lbC iX l lb  Reduces the Need for Balt,oui 
Stenting Dur ing  I~rimary lng lop lu ty ,  
RAPPORT Tr ia l  
LA. Barr, S.J. Branor, A.A. Jones, DJ. Mofitemo, M.B. Effron, EJ. Topoi. 
For the RAPPORT Investigators. Midwest Hearl Reseanch, Lombard. 
Illin~s, USA 
Background: Primary angmplasty for acute myocardial infarction (MI) is often 
complmated by transient or permanent abrupt vessel Closure due to dis- 
seclrons, rec~l, or thrombosis, whch frequently leads to bail~out stl~'ltit~. 
Abcixinlab, administered before angioplasty, has been shown to reduce the 
nsk of acute vessel closure, but has not been tested dunng primary PTCA. 
Methods: Patents (ptsl with acute MI <12 hr. were randomly allocated 
to placebo (P) or abciximab (A - 0.25 mcg,~g bolus and 12-hour mfusmn 
at 0.125 mcoJkg/min} as an adjunct to pnmery balloon angmplasty. Slanting 
was allowed for large dLseect~ons or acute/threatened vessel closure ('TIMI 
flow <2). 
Results: The need for stenting in the three groups (intention-to.treat -fl-r 
[242 P, 241A], any amount of study drug - DRUG [2131:), 226A], and interven- 
tion with study drag per protocol - I [170P, 179A]) is presented below. 
P A p value RR 
ITT 174% I1 6% 0057 33% 
DRUG 183% 11 5=° 0 031 38% 
I 20 6"* 12 3% 0G22 41'% 
Conclusron: By preventing platetet aggregation at the site of ba,oon 
inflation, abeiximab reduces the need for bail-out stenting dunng primary 
angioplasty for acute myocardial infarction. The effect was most pronounced 
in the group who received abciximab for ;he entire 12-hour period. Cost 
implications and potential for combined abctmmab and pnmary stenting need 
further exploration. 
t 1088-102 ] Abc ix imab Decreases  the Incidence and 
Magnitude of Non-O Wave Myocardial Infarction 
Assoc iated With Rotat ional  A themctomy 
G.A. Braden. WM. Love, RJ. Applegate, TM Young, D.C. Sane. Bm~rnan 
Gray School of Medicine. Winston-Salem. NC, USA 
Creatine kinase (CK) nse/non-Q wave MI (NQMI) is common following ro- 
tational atherectomy (RA) and may be assooated w~th long term adverse 
outcomes. Abciximab (ReoPm) decreases the incidence of NQM! following 
PTCA and DCA, however, the benefits of ReoPro during RA have not been 
previously assessed. Accordingly. we examined the effects of ReoPro on 
acute outcome during RA. 176 pts. received ReoPm (bolus + 12 hr infusion) 
and t50 pts. received heparin (Hep) only between 10/95 and 12/96. ReoPre 
pts. had lower ACT's (340 ± 6) vs. heparin (431 ± 8). p < 0.05. While ReoPro 
treated pts. had more angiographically complex anatomy (AHA/ACC B:~/C 
lesions 47.6% ReoPro vs. 22.9% non-ReoPro, p < 0.001). Vascular access 
complications were similar however more non-ReoPro pts. received trans- 
fusions (15.3% vs. 6.4%. p < 002). Thrembocytoponia (pH <100,000) was 
similar between the two groups (2.6 vs. 2.3%). CK rise following PTCRA: 
peak CK CK A 1-3, N1 ;3~N1 Any AbNt 
ReoPro 149 • 13 86 t 13 14% 3% 17% 
Non-ReoPro 354 +_ 100 278 ~ 9B 18°o 12°o 30% 
P <0.05 . 005 0.06 - 0.05 -005 
